CLINICAL TRIAL SUMMARY

MDACC Study No:2004-0223 (clinicaltrials.gov NCT No: NCT00412594)
Title:PHASE II STUDY OF 2-CHLORODEOXYADENOSINE (2CDA) FOLLOWED BY RITUXIMAB IN HAIRY CELL LEUKEMIA
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:2-Chlorodeoxyadenosine; Rituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if treatment with 2CDA
(cladribine) followed by treatment with rituximab can help to control HCL. The
safety of this combination treatment will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:2-Chlorodeoxyadenosine
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:No hospitalization required.
Supported By:N/A
Return Visit:Daily for 5 days, then weekly for 8 weeks then every three months for first
year. Patients can receive their treatment locally after the first dose of both
agents has been administered at M.D. Anderson.
Home Care:Patients can receive their 2CDA and Rituximab treatment locally after the first
dose of both agents has been administered at M.D. Anderson.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults